Janus Henderson Group PLC Takes $11.25 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Janus Henderson Group PLC bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 375,044 shares of the company’s stock, valued at approximately $11,251,000. Janus Henderson Group PLC owned 1.28% of Dianthus Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $25,000. Hussman Strategic Advisors Inc. bought a new position in shares of Dianthus Therapeutics in the first quarter worth about $630,000. StemPoint Capital LP purchased a new position in shares of Dianthus Therapeutics during the 1st quarter valued at about $1,304,000. Octagon Capital Advisors LP grew its stake in shares of Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after acquiring an additional 74,000 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in Dianthus Therapeutics in the 4th quarter worth approximately $1,404,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Down 5.9 %

Shares of Dianthus Therapeutics stock opened at $28.01 on Friday. The stock has a 50 day moving average price of $25.56 and a 200-day moving average price of $24.36. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The business had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.48 million. Sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Wedbush boosted their price objective on Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price on the stock. HC Wainwright started coverage on shares of Dianthus Therapeutics in a research note on Thursday, May 16th. They set a “buy” rating and a $40.00 target price for the company. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $45.00.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.